Rubicon Research Limited has completed the acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. The transaction was executed as a secondary acquisition under the terms agreed in the Share Purchase Agreement, as intimated to the stock exchanges. This development follows the company's earlier communication dated April 15, 2026.

Transaction Details

The acquisition involves the purchase of securities representing an 85% stake in Arinna Lifesciences Limited. The completion of this transaction marks a significant expansion for Rubicon Research Limited in the lifesciences sector. The deal was structured as a secondary acquisition, indicating the purchase of existing shares rather than new issuance.

Subsidiary Status

Following the completion of the acquisition, Arinna Lifesciences Limited has become a subsidiary of Rubicon Research Limited. This change in ownership structure will enable the company to consolidate the operations and financials of Arinna Lifesciences Limited going forward.

Regulatory Compliance

The intimation regarding the completion of this acquisition was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was addressed to both BSE Limited and National Stock Exchange of India Limited, with Rubicon Research Limited listed under scrip code 544578 on BSE and symbol RUBICON on NSE.

Rubicon Research Limited announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its R&D facility in Canada through an official regulatory disclosure dated April 24, 2026. The pharmaceutical company communicated this development to both BSE Limited and National Stock Exchange of India Limited under SEBI regulations.

USFDA Inspection Details

The USFDA conducted an unannounced inspection at Rubicon Research's R&D facility located in Concord, Ontario, Canada. The inspection was completed over a four-day period from April 20, 2026 to April 24, 2026, providing regulatory authorities with comprehensive oversight of the company's research and development operations.

Regulatory Compliance Achievement

The inspection concluded without any Form-483 being issued, representing a significant positive outcome for the company. A Form-483 typically lists observations of conditions or practices that may constitute violations of FDA regulations, so its absence indicates the facility met regulatory standards during the inspection period.

Official Communication Structure

The disclosure was formally communicated to stock exchanges through a letter signed by Company Secretary Deepashree Omkar Tanksale with digital signature authentication. The communication was addressed to the Listing Departments of both BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street and National Stock Exchange of India Limited at Exchange Plaza, Bandra Kurla Complex.

Regulatory Framework

The company made this disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to inform stock exchanges about material events that could impact investor decisions or share prices, ensuring transparency in corporate communications. The company emphasized its commitment to maintaining the highest standards of compliance and quality across its operations.